Huy V Nguyen, MD
Hematology/Oncology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 3 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Stanford Health Care · Sutter Medical Center, Sacramento. That is not proof they admit you there this week.
Plans that list them
3 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nguyen’s office at (650) 691-6174 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
3 of 3 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A87421 · Current
Licensed to practise in California · since 2018 · expires 2026-12-31 · University of Washington School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$2,135,811
Medicare paid this office $2,135,811 for 714 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 19 | $383,910 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 19 | $380,338 | None |
| Injection, vedolizumab, intravenous, 1 mg | 12 | $103,575 | None |
| Long return visit (40+ min) | 192 | $94,646 | $168 |
| Injection, tocilizumab, 1 mg | 14 | $62,554 | None |
See all 44 services
| Injection, pembrolizumab, 1 mg | 19 | $383,910 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 19 | $380,338 | None |
| Injection, vedolizumab, intravenous, 1 mg | 12 | $103,575 | None |
| Long return visit (40+ min) | 192 | $94,646 | $168 |
| Injection, tocilizumab, 1 mg | 14 | $62,554 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $32,732 | None |
| Administration of chemotherapy into vein, 1 hour or less | 98 | $28,709 | $141 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 17 | $28,326 | $16 |
| Return visit (30+ min) | 173 | $25,930 | $114 |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 11 | $21,005 | $109 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 24 | $15,422 | None |
| New patient visit (60+ min) | 73 | $13,660 | $187 |
| Injection, denosumab, 1 mg | 11 | $13,584 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 115 | $13,391 | $66 |
| New patient visit (45+ min) | 62 | $9,271 | $150 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $7,320 | $78 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 196 | $4,817 | $15 |
| Administration of additional new drug or substance into vein, 1 hour or less | 38 | $4,468 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $4,250 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,030 | $155 |
| Instillation of anti-cancer drug into bladder | 21 | $3,127 | $82 |
| Bcg live intravesical instillation, 1 mg | 15 | $2,848 | None |
| Administration of chemotherapy into vein, each additional hour | 31 | $2,486 | $29 |
| Administration of additional new drug or substance into vein using push technique | 20 | $2,462 | $59 |
| Injection of additional new drug or substance into vein | 63 | $2,405 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 30 | $2,253 | $20 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 12 | $2,184 | $182 |
| Injection of drug or substance into vein | 44 | $1,927 | $37 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 28 | $1,813 | $30 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $1,692 | $36 |
| Injection of drug or substance under skin or into muscle | 55 | $1,595 | $14 |
| Injection, zoledronic acid, 1 mg | 57 | $1,443 | None |
| Short return visit (20+ min) | 16 | $1,167 | $69 |
| Irrigation of implanted venous access drug delivery device | 15 | $882 | $27 |
| Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg | 11 | $808 | None |
| Injection, fosaprepitant, 1 mg | 24 | $709 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 19 | $506 | $20 |
| Injection, carboplatin, 50 mg | 12 | $320 | None |
| Injection, paclitaxel, 1 mg | 13 | $278 | None |
| Infusion, normal saline solution, 250 cc | 148 | $114 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 47 | $76 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 43 | $71 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 37 | $38 | None |
| Unclassified drugs | 12 | $8 | None |
Who their Medicare patients are
714 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 22% · Women 55% · Also on Medicaid 13% · Health risk score 1.71. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 69% · Cancer 35% · Chronic kidney disease 30% · Diabetes 29% · Coronary heart disease 25% · Atrial fibrillation 21% · Depression 17% · Heart failure 16% · COPD 14% · Stroke 8% · Dementia 7%.
The office billed $7,297,357, Medicare allowed $2,695,861 and paid $2,135,811; for 120,120 services of 133 kinds; $1,896,881 of it was for drugs given in the office and $238,930 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 714 | 120,120 | 77 | 1.71 | $7,297,357 | $2,135,811 |
| 2023 | 632 | 101,062 | 77 | 1.65 | $5,783,112 | $1,667,735 |
| 2022 | 637 | 93,190 | 77 | 1.68 | $5,210,017 | $1,698,555 |
| 2021 | 533 | 95,205 | 77 | 1.72 | $4,956,696 | $1,696,450 |
| 2020 | 478 | 72,732 | 76 | 1.93 | $3,858,940 | $1,242,775 |
| 2019 | 352 | 38,988 | 76 | 1.64 | $2,386,763 | $704,254 |
| 2018 | 34 | 4,913 | 71 | 1.13 | $488,566 | $84,562 |
| 2017 | 29 | 3,852 | 70 | 1.95 | $307,849 | $49,626 |
| 2016 | 27 | 1,831 | 72 | 2.01 | $83,781 | $17,401 |
| 2015 | 26 | 1,277 | 69 | 1.24 | $227,660 | $33,320 |
| 2014 | 30 | 3,504 | 70 | 1.50 | $327,377 | $55,929 |
| 2013 | 33 | 1,733 | 69 | 1.71 | $60,306 | $15,897 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 39 services
| Injection, pembrolizumab, 1 mg | 23 | $476,532 | None |
| Long return visit (40+ min) | 163 | $77,647 | $167 |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $59,296 | None |
| Injection, denosumab, 1 mg | 13 | $28,493 | None |
| Administration of chemotherapy into vein, 1 hour or less | 94 | $27,100 | $144 |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $26,034 | None |
| New patient visit (60+ min) | 115 | $22,888 | $199 |
| Return visit (30+ min) | 151 | $22,581 | $112 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 11 | $22,178 | $22 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $13,036 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 86 | $11,953 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $9,434 | $110 |
| New patient visit (45+ min) | 35 | $4,832 | $138 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $4,816 | $80 |
| Administration of additional new drug or substance into vein, 1 hour or less | 29 | $4,596 | $71 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,518 | $160 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 17 | $3,514 | $185 |
| Instillation of anti-cancer drug into bladder | 14 | $2,431 | $90 |
| Short return visit (20+ min) | 30 | $2,328 | $73 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 31 | $2,265 | $22 |
| Administration of chemotherapy into vein, each additional hour | 26 | $2,252 | $30 |
| Injection of drug or substance under skin or into muscle | 56 | $2,187 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 30 | $2,082 | $31 |
| Administration of additional new drug or substance into vein using push technique | 14 | $1,995 | $60 |
| Injection of additional new drug or substance into vein | 47 | $1,898 | $17 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $1,717 | $37 |
| Injection of drug or substance into vein | 28 | $1,387 | $37 |
| Injection, zoledronic acid, 1 mg | 34 | $878 | None |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $865 | $79 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $585 | None |
| Irrigation of implanted venous access drug delivery device | 12 | $563 | $27 |
| Injection, fosaprepitant, 1 mg | 21 | $532 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $460 | $21 |
| Infusion into a vein for hydration, each additional hour | 17 | $392 | $14 |
| Infusion, normal saline solution, 250 cc | 122 | $99 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 40 | $69 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 36 | $62 | None |
| Infusion, normal saline solution , 1000 cc | 15 | $58 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 18 | $23 | None |
2022: 40 services
| Injection, pembrolizumab, 1 mg | 25 | $395,277 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12 | $150,440 | None |
| Injection, pemetrexed, not otherwise specified, 10 mg | 11 | $82,126 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 17 | $81,674 | None |
| Long return visit (40+ min) | 129 | $70,488 | $164 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $41,063 | None |
| Injection, tocilizumab, 1 mg | 11 | $39,347 | None |
| Administration of chemotherapy into vein, 1 hour or less | 118 | $29,656 | $151 |
| New patient visit (60+ min) | 124 | $24,268 | $196 |
| Return visit (30+ min) | 133 | $22,798 | $109 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $15,567 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 21 | $11,932 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 94 | $11,415 | $74 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,811 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $5,463 | $93 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $5,071 | $83 |
| Administration of additional new drug or substance into vein, 1 hour or less | 37 | $4,734 | $73 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 21 | $4,098 | $186 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 59 | $3,629 | $32 |
| Short return visit (20+ min) | 36 | $3,094 | $84 |
| Injection of additional new drug or substance into vein | 60 | $2,920 | $17 |
| New patient visit (45+ min) | 16 | $2,248 | $141 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $1,950 | $35 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 27 | $1,766 | $22 |
| Administration of chemotherapy into vein, each additional hour | 31 | $1,641 | $31 |
| Injection of drug or substance under skin or into muscle | 54 | $1,573 | $14 |
| Bcg live intravesical instillation, 1 mg | 13 | $1,561 | None |
| Instillation of anti-cancer drug into bladder | 16 | $1,523 | $90 |
| Administration of additional new drug or substance into vein using push technique | 17 | $1,438 | $63 |
| Injection of drug or substance into vein | 20 | $1,014 | $39 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $840 | $76 |
| Injection, zoledronic acid, 1 mg | 31 | $834 | None |
| Injection, fosaprepitant, 1 mg | 27 | $694 | None |
| Injection, paclitaxel, 1 mg | 24 | $632 | None |
| Injection, carboplatin, 50 mg | 29 | $590 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $580 | None |
| Irrigation of implanted venous access drug delivery device | 12 | $354 | $25 |
| Injection, dexamethasone sodium phosphate, 1 mg | 60 | $88 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 60 | $55 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 33 | $49 | None |
2021: 33 services
| Injection, pembrolizumab, 1 mg | 18 | $306,607 | None |
| Long return visit (40+ min) | 130 | $72,511 | $169 |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 12 | $53,195 | None |
| Injection, denosumab, 1 mg | 14 | $29,915 | None |
| Administration of chemotherapy into vein, 1 hour or less | 88 | $27,243 | $161 |
| New patient visit (60+ min) | 121 | $25,339 | $209 |
| Return visit (30+ min) | 131 | $21,959 | $113 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 85 | $10,108 | $80 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 16 | $9,454 | $1 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $7,749 | $89 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $6,998 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $6,714 | $93 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $4,658 | $78 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 37 | $3,959 | $34 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 18 | $3,414 | $180 |
| Injection of additional new drug or substance into vein | 44 | $2,473 | $18 |
| Administration of chemotherapy into vein, each additional hour | 30 | $2,181 | $33 |
| Telephone medical discussion with physician, 11-20 minutes | 21 | $1,824 | $73 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,614 | $108 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 20 | $1,442 | $23 |
| Injection of drug or substance under skin or into muscle | 46 | $1,435 | $14 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $1,187 | $35 |
| Injection, fosaprepitant, 1 mg | 15 | $1,065 | None |
| Injection of drug or substance into vein | 18 | $938 | $45 |
| Injection, zoledronic acid, 1 mg | 22 | $876 | None |
| Irrigation of implanted venous access drug delivery device | 17 | $694 | $32 |
| Injection, paclitaxel, 1 mg | 11 | $416 | None |
| Injection, carboplatin, 50 mg | 15 | $298 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $264 | $24 |
| Injection, dexamethasone sodium phosphate, 1 mg | 39 | $93 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 41 | $59 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 26 | $40 | None |
| Infusion, normal saline solution, 250 cc | 15 | $9 | None |
2020: 32 services
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $59,374 | None |
| Return visit (30+ min) | 153 | $43,242 | $100 |
| Injection, infliximab, excludes biosimilar, 10 mg | 15 | $42,366 | None |
| Administration of chemotherapy into vein, 1 hour or less | 91 | $24,948 | $150 |
| New patient visit (60+ min) | 119 | $21,786 | $183 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 76 | $8,367 | $73 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $4,639 | $84 |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $4,603 | $72 |
| Long return visit (40+ min) | 34 | $4,417 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $3,184 | $96 |
| Injection, fosaprepitant, 1 mg | 14 | $3,024 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 43 | $2,789 | $32 |
| Telephone medical discussion with physician, 11-20 minutes | 25 | $2,576 | $72 |
| Administration of chemotherapy into vein, each additional hour | 31 | $2,557 | $31 |
| Injection of additional new drug or substance into vein | 53 | $2,321 | $17 |
| New patient visit (45+ min) | 16 | $2,307 | $144 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 20 | $1,536 | $22 |
| Injection of drug or substance under skin or into muscle | 38 | $942 | $14 |
| Short return visit (20+ min) | 11 | $871 | $73 |
| Injection, zoledronic acid, 1 mg | 24 | $868 | None |
| Injection of drug or substance into vein | 18 | $831 | $40 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $769 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $623 | $33 |
| Injection, paclitaxel, 1 mg | 15 | $586 | None |
| Injection, carboplatin, 50 mg | 19 | $504 | None |
| Irrigation of implanted venous access drug delivery device | 13 | $446 | $28 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $310 | $24 |
| Collection of blood sample from implanted device | 11 | $300 | $25 |
| Injection, dexamethasone sodium phosphate, 1 mg | 41 | $78 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 44 | $70 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 30 | $29 | None |
| Infusion, normal saline solution, 250 cc | 11 | $6 | None |
2019: 23 services
| Administration of chemotherapy into vein, 1 hour or less | 66 | $15,236 | $141 |
| New patient visit (60+ min) | 79 | $14,818 | $188 |
| Return visit (30+ min) | 71 | $12,597 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $4,555 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 44 | $4,218 | $74 |
| Injection, fosaprepitant, 1 mg | 13 | $3,498 | None |
| Long return visit (40+ min) | 22 | $3,415 | $131 |
| New patient visit (45+ min) | 20 | $3,056 | $153 |
| Administration of chemotherapy into vein, each additional hour | 31 | $2,216 | $31 |
| Administration of additional new drug or substance into vein, 1 hour or less | 22 | $1,941 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 32 | $1,583 | $30 |
| Injection of additional new drug or substance into vein | 44 | $1,518 | $17 |
| New patient visit (30+ min) | 11 | $1,122 | $102 |
| Short return visit (20+ min) | 16 | $913 | $54 |
| Injection of drug or substance under skin or into muscle | 34 | $845 | $16 |
| Injection, zoledronic acid, 1 mg | 17 | $681 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 12 | $672 | $22 |
| Injection of drug or substance into vein | 14 | $562 | $40 |
| Injection, paclitaxel, 1 mg | 12 | $375 | None |
| Injection, carboplatin, 50 mg | 12 | $298 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 25 | $45 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 28 | $43 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $24 | None |
2018: 1 service
| Short return visit (20+ min) | 11 | $836 | $42 |
2017: 2 services
| Administration of chemotherapy into vein, 1 hour or less | 11 | $1,879 | $111 |
| Short return visit (20+ min) | 11 | $676 | $38 |
2014: 1 service
| Return visit (30+ min) | 11 | $2,094 | $60 |
2013: 1 service
| Return visit (30+ min) | 19 | $2,148 | $65 |
Medicaid work
$32,402 in 2019
Medicaid paid $32,402 for 54 billed services this clinician did in 2019, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 54 | $32,402 |
| 2019 | 54 | 1 | 14 | $32,402 |
Drugs they prescribed that Part D paid
$3,532,202
Pharmacies billed $3,532,202 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (31 of 1,310) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
829 generic and fewer than 11 brand-name prescriptions · $3,532,202 in drug cost · 14 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Revlimid | 30 | $572,716 | $19,091 |
| Xtandi | 31 | $438,244 | $14,137 |
| Brukinsa | 29 | $437,176 | $15,075 |
| Tagrisso | 21 | $347,530 | $16,549 |
| Tasigna | 12 | $227,158 | $18,930 |
See all 22 drugs
| Revlimid | 30 | $572,716 | $19,091 |
| Xtandi | 31 | $438,244 | $14,137 |
| Brukinsa | 29 | $437,176 | $15,075 |
| Tagrisso | 21 | $347,530 | $16,549 |
| Tasigna | 12 | $227,158 | $18,930 |
| Erleada | 11 | $170,853 | $15,532 |
| Eliquis | 206 | $147,771 | $717 |
| Xarelto | 30 | $22,735 | $758 |
| Fondaparinux | 12 | $12,836 | $1,070 |
| Abiraterone Acetate | 58 | $12,433 | $214 |
| Hydroxyurea | 60 | $1,993 | $33 |
| Acyclovir | 84 | $1,761 | $21 |
| Letrozole | 52 | $1,047 | $20 |
| Dexamethasone | 47 | $940 | $20 |
| Imatinib Mesylate | 12 | $918 | $77 |
| Prochlorperazine Maleate | 76 | $850 | $11 |
| Anastrozole | 31 | $757 | $24 |
| Tamoxifen Citrate | 26 | $538 | $21 |
| Prednisone | 96 | $407 | $4 |
| Ondansetron | 44 | $379 | $9 |
| Levothyroxine | 16 | $341 | $21 |
| Gabapentin | 11 | $42 | $4 |
Year by year
| 2024 | 1,310 | 210 | 2% (31) | None | $3,532,202 |
| 2023 | 882 | 175 | 2% (17) | None | $2,061,972 |
| 2022 | 732 | 123 | 3% (24) | None | $1,937,114 |
| 2021 | 621 | 100 | 4% (27) | 25% | $965,502 |
| 2020 | 478 | 94 | 6% (30) | 20% | $745,787 |
| 2019 | 765 | 192 | 10% (76) | 31% | $1,897,610 |
| 2018 | 1,297 | 209 | 12% (159) | None | $4,515,042 |
| 2017 | 1,210 | 181 | 10% (116) | None | $3,501,606 |
| 2016 | 1,256 | 198 | 9% (110) | 44% | $3,250,663 |
| 2015 | 836 | 160 | 13% (109) | 40% | $2,039,016 |
| 2014 | 1,102 | 210 | 13% (144) | 32% | $1,390,901 |
| 2013 | 827 | 181 | 15% (125) | 30% | $587,124 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Revlimid | 15 | $293,225 | $19,548 |
| Tagrisso | 16 | $290,219 | $18,139 |
| Erleada | 16 | $262,506 | $16,407 |
| Brukinsa | 13 | $212,265 | $16,328 |
| Xtandi | 11 | $154,821 | $14,075 |
| Eliquis | 114 | $84,508 | $741 |
| Pegasys | 13 | $55,260 | $4,251 |
| Imatinib Mesylate | 20 | $36,296 | $1,815 |
| Fondaparinux | 12 | $22,550 | $1,879 |
| Xarelto | 20 | $18,750 | $937 |
| Abiraterone Acetate | 40 | $9,477 | $237 |
| Anastrozole | 46 | $2,073 | $45 |
| Acyclovir | 54 | $1,489 | $28 |
| Hydroxyurea | 39 | $1,343 | $34 |
| Letrozole | 34 | $966 | $28 |
| Potassium Chloride | 17 | $502 | $30 |
| Levothyroxine | 20 | $487 | $24 |
| Prochlorperazine Maleate | 46 | $465 | $10 |
| Dexamethasone | 23 | $451 | $20 |
| Ondansetron | 31 | $343 | $11 |
| Prednisone | 62 | $330 | $5 |
| Latanoprost | 12 | $164 | $14 |
| Amlodipine Besylate | 11 | $104 | $9 |
2022: 21 drugs
| Tagrisso | 21 | $366,950 | $17,474 |
| Revlimid | 20 | $366,506 | $18,325 |
| Erleada | 18 | $264,490 | $14,694 |
| Sprycel | 12 | $202,480 | $16,873 |
| Xtandi | 11 | $141,475 | $12,861 |
| Pegasys | 12 | $48,206 | $4,017 |
| Eliquis | 60 | $46,878 | $781 |
| Fondaparinux | 12 | $19,631 | $1,636 |
| Imatinib Mesylate | 17 | $11,859 | $698 |
| Xarelto | 13 | $11,544 | $888 |
| Hydroxyurea | 31 | $1,774 | $57 |
| Acyclovir | 81 | $1,596 | $20 |
| Anastrozole | 44 | $1,424 | $32 |
| Letrozole | 21 | $625 | $30 |
| Prochlorperazine Maleate | 35 | $423 | $12 |
| Prednisone | 37 | $388 | $10 |
| Dexamethasone | 14 | $292 | $21 |
| Ondansetron | 13 | $233 | $18 |
| Sulfamethoxazole-Trimethoprim | 38 | $143 | $4 |
| Amlodipine Besylate | 12 | $38 | $3 |
| Hydrochlorothiazide | 13 | $32 | $2 |
2021: 16 drugs
| Revlimid | 17 | $285,174 | $16,775 |
| Imatinib Mesylate | 12 | $52,081 | $4,340 |
| Eliquis | 52 | $39,592 | $761 |
| Xarelto | 19 | $16,810 | $885 |
| Acyclovir | 58 | $1,610 | $28 |
| Hydroxyurea | 27 | $1,439 | $53 |
| Anastrozole | 33 | $1,020 | $31 |
| Prochlorperazine Maleate | 61 | $747 | $12 |
| Diphenoxylate-Atropine | 15 | $741 | $49 |
| Ondansetron | 28 | $527 | $19 |
| Dexamethasone | 21 | $335 | $16 |
| Prednisone | 31 | $229 | $7 |
| Ketoconazole | 16 | $223 | $14 |
| Lorazepam | 16 | $59 | $4 |
| Sulfamethoxazole-Trimethoprim | 16 | $50 | $3 |
| Amlodipine Besylate | 14 | $28 | $2 |
2020: 13 drugs
| Revlimid | 26 | $381,601 | $14,677 |
| Abiraterone Acetate | 11 | $34,414 | $3,129 |
| Eliquis | 17 | $11,087 | $652 |
| Xarelto | 13 | $11,004 | $846 |
| Hydroxyurea | 23 | $1,388 | $60 |
| Acyclovir | 43 | $1,006 | $23 |
| Prochlorperazine Maleate | 53 | $735 | $14 |
| Dexamethasone | 33 | $637 | $19 |
| Anastrozole | 13 | $454 | $35 |
| Ondansetron | 28 | $437 | $16 |
| Doxycycline Hyclate | 13 | $330 | $25 |
| Prednisone | 26 | $177 | $7 |
| Sulfamethoxazole-Trimethoprim | 20 | $120 | $6 |
2019: 21 drugs
| Tagrisso | 29 | $447,703 | $15,438 |
| Revlimid | 18 | $262,076 | $14,560 |
| Xtandi | 19 | $188,059 | $9,898 |
| Imbruvica | 12 | $148,573 | $12,381 |
| Abiraterone Acetate | 23 | $69,505 | $3,022 |
| Zarxio | 14 | $21,409 | $1,529 |
| Procrit | 13 | $8,373 | $644 |
| Eliquis | 13 | $6,852 | $527 |
| Imatinib Mesylate | 22 | $6,599 | $300 |
| Exemestane | 14 | $4,260 | $304 |
| Acyclovir | 48 | $1,226 | $26 |
| Hydroxyurea | 22 | $1,086 | $49 |
| Dexamethasone | 29 | $943 | $33 |
| Anastrozole | 29 | $687 | $24 |
| Ondansetron | 31 | $510 | $16 |
| Prednisone | 48 | $489 | $10 |
| Lactulose | 18 | $339 | $19 |
| Oxycodone | 18 | $320 | $18 |
| Hydrocodone-Acetaminophen | 15 | $244 | $16 |
| Prochlorperazine Maleate | 14 | $139 | $10 |
| Amlodipine Besylate | 16 | $109 | $7 |
2018: 35 drugs
| Tagrisso | 54 | $843,919 | $15,628 |
| Revlimid | 52 | $740,256 | $14,236 |
| Zytiga | 68 | $670,153 | $9,855 |
| Xtandi | 61 | $529,852 | $8,686 |
| Jakafi | 24 | $278,535 | $11,606 |
| Tarceva | 24 | $220,132 | $9,172 |
| Imbruvica | 15 | $176,883 | $11,792 |
| Sprycel | 14 | $158,495 | $11,321 |
| Promacta | 23 | $112,388 | $4,886 |
| Iressa | 11 | $84,242 | $7,658 |
| Procrit | 21 | $23,574 | $1,123 |
| Imatinib Mesylate | 47 | $22,669 | $482 |
| Oxymorphone Hcl Er | 12 | $21,362 | $1,780 |
| Leukeran | 12 | $10,015 | $835 |
| Fentanyl | 26 | $4,335 | $167 |
| Exemestane | 13 | $4,033 | $310 |
| Anagrelide | 11 | $2,882 | $262 |
| Dexamethasone | 72 | $2,467 | $34 |
| Acyclovir | 59 | $1,977 | $34 |
| Hydroxyurea | 27 | $1,894 | $70 |
| Anastrozole | 54 | $1,407 | $26 |
| Morphine Sulfate | 23 | $1,298 | $56 |
| Prednisone | 96 | $1,135 | $12 |
| Hydromorphone | 23 | $1,082 | $47 |
| Tamoxifen Citrate | 19 | $1,057 | $56 |
| Clindamycin Phosphate | 14 | $955 | $68 |
| Oxycodone | 29 | $832 | $29 |
| Lactulose | 34 | $705 | $21 |
| Gabapentin | 20 | $534 | $27 |
| Ondansetron | 31 | $431 | $14 |
| Hydrocodone-Acetaminophen | 24 | $319 | $13 |
| Bicalutamide | 15 | $294 | $20 |
| Morphine Sulfate Er | 11 | $255 | $23 |
| Allopurinol | 11 | $201 | $18 |
| K-Tab Er | 14 | $180 | $13 |
2017: 39 drugs
| Revlimid | 46 | $561,276 | $12,202 |
| Tarceva | 36 | $303,415 | $8,428 |
| Imbruvica | 27 | $298,419 | $11,053 |
| Xtandi | 32 | $282,503 | $8,828 |
| Tagrisso | 17 | $262,507 | $15,442 |
| Zytiga | 21 | $182,892 | $8,709 |
| Iressa | 23 | $168,437 | $7,323 |
| Votrient | 15 | $163,828 | $10,922 |
| Nexavar | 11 | $143,146 | $13,013 |
| Promacta | 25 | $116,665 | $4,667 |
| Lonsurf | 13 | $112,362 | $8,643 |
| Gleevec | 11 | $97,728 | $8,884 |
| Arixtra | 12 | $51,558 | $4,297 |
| Imatinib Mesylate | 31 | $32,442 | $1,047 |
| Leukeran | 12 | $20,092 | $1,674 |
| Opana Er | 12 | $18,823 | $1,569 |
| Fentanyl | 23 | $4,467 | $194 |
| Exemestane | 15 | $4,410 | $294 |
| Gengraf | 16 | $3,116 | $195 |
| Hydroxyurea | 35 | $2,702 | $77 |
| Pradaxa | 12 | $2,326 | $194 |
| Acyclovir | 57 | $1,738 | $30 |
| Anastrozole | 60 | $1,687 | $28 |
| Tamoxifen Citrate | 19 | $1,180 | $62 |
| Dexamethasone | 79 | $1,103 | $14 |
| Clindamycin Phosphate | 13 | $1,038 | $80 |
| Prednisone | 62 | $957 | $15 |
| Oxycodone | 26 | $752 | $29 |
| Hydromorphone | 11 | $590 | $54 |
| Gabapentin | 15 | $555 | $37 |
| Morphine Sulfate | 12 | $465 | $39 |
| Ondansetron | 31 | $462 | $15 |
| Hydrocodone-Acetaminophen | 14 | $363 | $26 |
| Lactulose | 14 | $311 | $22 |
| Letrozole | 11 | $283 | $26 |
| Levothyroxine | 11 | $198 | $18 |
| K-Tab Er | 17 | $197 | $12 |
| Furosemide | 14 | $184 | $13 |
| Trazodone | 11 | $76 | $7 |
2016: 35 drugs
| Revlimid | 39 | $450,951 | $11,563 |
| Tarceva | 55 | $404,369 | $7,352 |
| Gleevec | 52 | $391,712 | $7,533 |
| Xtandi | 41 | $380,302 | $9,276 |
| Imbruvica | 35 | $373,173 | $10,662 |
| Votrient | 22 | $193,339 | $8,788 |
| Tasigna | 18 | $170,815 | $9,490 |
| Zytiga | 16 | $126,577 | $7,911 |
| Nexavar | 14 | $118,220 | $8,444 |
| Promacta | 23 | $103,961 | $4,520 |
| Zarxio | 33 | $67,933 | $2,059 |
| Leukeran | 11 | $20,035 | $1,821 |
| Procrit | 11 | $11,706 | $1,064 |
| Anastrozole | 83 | $2,841 | $34 |
| Tacrolimus | 17 | $2,692 | $158 |
| Gengraf | 18 | $2,493 | $139 |
| Hydroxyurea | 27 | $2,249 | $83 |
| Acyclovir | 59 | $2,187 | $37 |
| Fentanyl | 14 | $2,048 | $146 |
| Anagrelide | 12 | $1,912 | $159 |
| Prednisone | 90 | $1,644 | $18 |
| Tamoxifen Citrate | 22 | $1,367 | $62 |
| Clindamycin Phosphate | 13 | $1,293 | $99 |
| Hydrocodone-Acetaminophen | 25 | $1,099 | $44 |
| Morphine Sulfate | 16 | $871 | $54 |
| Ondansetron | 43 | $705 | $16 |
| Dexamethasone | 33 | $701 | $21 |
| Oxycodone | 16 | $612 | $38 |
| Gabapentin | 13 | $569 | $44 |
| Letrozole | 11 | $443 | $40 |
| Lactulose | 15 | $311 | $21 |
| K-Tab Er | 20 | $310 | $16 |
| Alendronate | 17 | $254 | $15 |
| Allopurinol | 12 | $198 | $16 |
| Lidocaine Hcl Viscous | 16 | $195 | $12 |
2015: 25 drugs
| Gleevec | 37 | $354,629 | $9,585 |
| Xtandi | 39 | $341,705 | $8,762 |
| Revlimid | 25 | $235,593 | $9,424 |
| Tarceva | 25 | $169,406 | $6,776 |
| Zytiga | 22 | $168,470 | $7,658 |
| Nexavar | 19 | $162,328 | $8,544 |
| Afinitor | 13 | $138,399 | $10,646 |
| Promacta | 14 | $48,253 | $3,447 |
| Leukeran | 16 | $18,565 | $1,160 |
| Anastrozole | 76 | $3,087 | $41 |
| Hydroxyurea | 30 | $2,428 | $81 |
| Anagrelide | 14 | $2,363 | $169 |
| Fentanyl | 18 | $2,314 | $129 |
| Acyclovir | 50 | $2,133 | $43 |
| Tamoxifen Citrate | 25 | $1,534 | $61 |
| Oxycodone | 14 | $1,129 | $81 |
| Prednisone | 57 | $1,093 | $19 |
| Hydrocodone-Acetaminophen | 26 | $1,086 | $42 |
| Morphine Sulfate Er | 15 | $825 | $55 |
| Hydromorphone | 17 | $816 | $48 |
| Letrozole | 15 | $440 | $29 |
| Lactulose | 16 | $367 | $23 |
| Alendronate | 19 | $277 | $15 |
| Ondansetron | 16 | $259 | $16 |
| Dexamethasone | 14 | $254 | $18 |
2014: 28 drugs
| Gleevec | 38 | $309,934 | $8,156 |
| Zytiga | 50 | $290,655 | $5,813 |
| Revlimid | 25 | $188,842 | $7,554 |
| Tarceva | 12 | $79,474 | $6,623 |
| Neupogen | 30 | $57,882 | $1,929 |
| Procrit | 17 | $17,079 | $1,005 |
| Opana Er | 14 | $11,872 | $848 |
| Leukeran | 11 | $8,900 | $809 |
| Exemestane | 15 | $6,496 | $433 |
| Oxycodone | 39 | $3,514 | $90 |
| Anastrozole | 95 | $3,075 | $32 |
| Fentanyl | 19 | $2,458 | $129 |
| Hydroxyurea | 45 | $2,182 | $48 |
| Acyclovir | 47 | $2,011 | $43 |
| Anagrelide | 11 | $1,653 | $150 |
| Morphine Sulfate Er | 30 | $1,493 | $50 |
| Prednisone | 100 | $1,217 | $12 |
| Tamoxifen Citrate | 21 | $1,172 | $56 |
| Ondansetron | 56 | $972 | $17 |
| Dexamethasone | 52 | $839 | $16 |
| Lactulose | 21 | $480 | $23 |
| Hydrocodone-Acetaminophen | 13 | $275 | $21 |
| Prochlorperazine Maleate | 17 | $232 | $14 |
| Amlodipine Besylate | 22 | $228 | $10 |
| Alendronate | 13 | $188 | $14 |
| Sulfamethoxazole-Trimethoprim | 13 | $151 | $12 |
| Levothyroxine | 12 | $128 | $11 |
| Zolpidem | 14 | $120 | $9 |
2013: 17 drugs
| Zytiga | 23 | $140,655 | $6,115 |
| Revlimid | 13 | $79,219 | $6,094 |
| Procrit | 57 | $42,760 | $750 |
| Neupogen | 18 | $31,799 | $1,767 |
| Anastrozole | 115 | $3,586 | $31 |
| Oxycodone | 40 | $3,264 | $82 |
| Hydroxyurea | 49 | $2,861 | $58 |
| Acyclovir | 54 | $2,281 | $42 |
| Fentanyl | 18 | $1,996 | $111 |
| Tamoxifen Citrate | 11 | $684 | $62 |
| Hydrocodone-Acetaminophen | 26 | $546 | $21 |
| Prednisone | 44 | $486 | $11 |
| Ondansetron | 29 | $473 | $16 |
| Morphine Sulfate | 13 | $384 | $30 |
| Dexamethasone | 30 | $332 | $11 |
| Amlodipine Besylate | 20 | $201 | $10 |
| Zolpidem | 20 | $163 | $8 |
Money from drug and device companies
$754 in 2025
| 2025 | 13 | 22 | None | $754 |
| 2024 | 6 | 7 | None | $374 |
| 2023 | 2 | 2 | None | $39 |
| 2022 | 1 | 2 | None | $47 |
| 2021 | 1 | 1 | None | $26 |
| 2020 | 1 | 1 | None | $123 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $212 | 5 payments
|
| Janssen Biotech | Rybrevant | $161 | 2 payments
|
| Abbvie | Venclexta | $58 | 2 payments
|
| Daiichi Sankyo | Datroway | $49 | 2 payments
|
| Pfizer | Ibrance | $41 | 2 payments
|
| GlaxoSmithKline | Blenrep | $38 | 2 payments
|
See all 22 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-25 | Enhertu | $26 |
| Daiichi Sankyo | Meals · 2025-11-20 | Datroway | $26 |
| Iovance Biotherapeutics | Meals · 2025-11-13 | Amtagvi | $22 |
| Incyte | Meals · 2025-11-10 | Zynyz | $20 |
| GlaxoSmithKline | Meals · 2025-11-06 | Blenrep | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-19 | Calquence | $28 |
| Recordati Rare Diseases Inc. | Meals · 2025-09-10 | Enjaymo | $35 |
| Daiichi Sankyo | Meals · 2025-09-05 | Datroway | $23 |
| Abbvie | Meals · 2025-09-05 | Venclexta | $32 |
| Janssen Biotech | Meals · 2025-08-29 | Talvey | $36 |
| Pfizer | Meals · 2025-07-31 | Ibrance | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-29 | None | $7 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-29 | None | $26 |
| Abbvie | Meals · 2025-07-22 | Imbruvica | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Lynparza | $125 |
| Array Biopharma | Meals · 2025-07-08 | Lorbrena | $25 |
| GlaxoSmithKline | Meals · 2025-06-30 | Ojjaara | $17 |
| Janssen Biotech | Meals · 2025-06-26 | Rybrevant | $125 |
| Kite Pharma | Meals · 2025-05-23 | Yescarta | $27 |
| Pfizer | Education · 2025-04-28 | Ibrance | $16 |
| Merck Sharp & Dohme | Meals · 2025-04-14 | Keytruda | $32 |
| Stemline Therapeutics | Meals · 2025-01-13 | Orserdu | $34 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $374
| AstraZeneca Pharmaceuticals LP | Lynparza | $144 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Onureg | $122 | 1 payment
|
| Astellas Pharma US | None | $45 | 1 payment
|
| Genentech USA | Vabysmo | $25 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $22 | 1 payment
|
| Daiichi Sankyo | Enhertu | $17 | 1 payment
|
2023: $39
| Genentech USA | Vabysmo | $26 | 1 payment
|
| Janssen Pharmaceuticals | None | $13 | 1 payment
|
2022: $47
| Genentech USA | Vabysmo | $47 | 2 payments
|
2021: $26
| Pfizer | Inlyta | $26 | 1 payment
|
2020: $123
| Regeneron Healthcare Solutions | Eylea | $123 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · The Compassher2 Trials Comprehensive Use of Pathologic Response Assessment To Optimize Therapy in Her2positive Breast Cancer Compassher2 Residual Disease Rd A Doubleblinded Phase III Randomized Trial of Tdm1 Compared With Tdm1 and Tucatinib · 2024 | Their institution | $10,000 |
Professional record
- NPI
- 1770659252
- Licence
- CA A87421, HI MD-15305California A87421: Current · expires 2026-12-31
- Trained
- University of Washington School of Medicine, 2002
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A874210, HI 637259-01
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2350 W El Camino Real Fl 2, Mountain View, CA, 94040
- NPI first listed
- 2006-11-28
- NPI last updated
- 2019-06-04
This is when the NPI record was last certified, not a medical board exam.